Stanley-Laman Group’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $258K | Hold |
666
| – | – | 0.03% | 281 |
|
|
2026
Q1 | $195K | Sell |
666
-272
| -29% | -$89.4K | 0.02% | 278 |
|
|
2025
Q4 | $329K | Buy |
938
+272
| +41% | +$91.9K | 0.04% | 252 |
|
|
2025
Q3 | $215K | Sell |
666
-7,636
| -92% | -$2.37M | 0.03% | 244 |
|
|
2025
Q2 | $3.23M | Sell |
8,302
-653
| -7% | -$263K | 0.48% | 95 |
|
|
2025
Q1 | $3.9M | Buy |
8,955
+747
| +9% | +$300K | 0.6% | 67 |
|
|
2024
Q4 | $3.03M | Buy |
8,208
+648
| +9% | +$271K | 0.43% | 105 |
|
|
2024
Q3 | $3.93M | Sell |
7,560
-266
| -3% | -$142K | 0.55% | 80 |
|
|
2024
Q2 | $4.24M | Buy |
7,826
+357
| +5% | +$189K | 0.61% | 65 |
|
|
2024
Q1 | $3.87M | Sell |
7,469
-39
| -0.5% | -$19.4K | 0.54% | 84 |
|
|
2023
Q4 | $3.54M | Sell |
7,508
-107
| -1% | -$49.5K | 0.54% | 75 |
|
|
2023
Q3 | $3.32M | Sell |
7,615
-194
| -2% | -$88K | 0.57% | 72 |
|
|
2023
Q2 | $3.47M | Buy |
7,809
+648
| +9% | +$299K | 0.57% | 74 |
|
|
2023
Q1 | $3.29M | Buy |
7,161
+6,495
| +975% | +$3.09M | 0.59% | 74 |
|
|
2022
Q4 | $342K | Sell |
666
-466
| -41% | -$237K | 0.07% | 177 |
|
|
2022
Q3 | $514K | Hold |
1,132
| – | – | 0.1% | 170 |
|
|
2022
Q2 | $546K | Sell |
1,132
-229
| -17% | -$113K | 0.1% | 190 |
|
|
2022
Q1 | $669K | Buy |
1,361
+679
| +100% | +$310K | 0.09% | 195 |
|
|
2021
Q4 | $316K | Hold |
682
| – | – | 0.04% | 233 |
|
|
2021
Q3 | $254K | Hold |
682
| – | – | 0.03% | 244 |
|
|
2021
Q2 | $260K | Hold |
682
| – | – | 0.04% | 236 |
|
|
2021
Q1 | $245K | Hold |
682
| – | – | 0.04% | 231 |
|
|
2020
Q4 | $219K | Buy |
+682
| New | +$209K | 0.04% | 227 |
|
|
2020
Q1 | – | Sell |
-666
| Closed | -$201K | – | 266 |
|
|
2019
Q4 | $201K | Buy |
+666
| New | +$183K | 0.05% | 262 |
|
|
2017
Q4 | – | Sell |
-3,726
| Closed | -$707K | – | 278 |
|
|
2017
Q3 | $707K | Buy |
3,726
+470
| +14% | +$89.5K | 0.19% | 131 |
|
|
2017
Q2 | $613K | Buy |
3,256
+25
| +0.8% | +$4.49K | 0.17% | 131 |
|
|
2017
Q1 | $534K | Sell |
3,231
-19,148
| -86% | -$3.05M | 0.14% | 159 |
|
|
2016
Q4 | $3.22M | Buy |
22,379
+11,251
| +101% | +$1.51M | 1% | 10 |
|
|
2016
Q3 | $1.39M | Buy |
11,128
+1,607
| +17% | +$207K | 0.57% | 39 |
|
|
2016
Q2 | $1.25M | Buy |
+9,521
| New | +$1.3M | 0.49% | 52 |
|
Other funds holding ELV
Stanley-Laman Group's ELV Position: Q2 2026 in Review
Stanley-Laman Group held its Elevance Health (ELV) position steady in Q2 2026 at 666 shares worth $258K. The position accounts for 0.03% of the portfolio, ranked #281.
Stanley-Laman Group first reported a position in ELV in Q2 2016 and has held it in 30 quarters since. The position peaked at $4.24M in Q2 2024. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Stanley-Laman Group held 666 shares of Elevance Health worth $258K as of Q2 2026.
- Stanley-Laman Group left its Elevance Health share count unchanged in Q2 2026.
- Elevance Health made up 0.03% of Stanley-Laman Group's portfolio in Q2 2026, its #281 holding.
- Stanley-Laman Group first reported a position in Elevance Health in Q2 2016 and has held it in 30 quarters since.
- Stanley-Laman Group's Elevance Health position peaked at $4.24M in Q2 2024.
- 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.